Catabasis Pharmaceuticals
| Region | Nordamerika |
| ISIN | US14875P2065 |
| Sektor | Biotechnologie |
| Website | https://www.catabasis.com/ |
At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. Our global Phase 3 PolarisDMD trial is currently enrolling boys affected by Duchenne. For more information on edasalonexent and our Phase 3 PolarisDMD trial, please visit www.catabasis.com or www.twitter.com/catabasispharma.
| Titel | Autor | Datum |
|---|---|---|
|
Der Tenbagger-Kandidat für 2020!
|
sharedeals | translation missing: de.datetime.time_ago_in_words.almost_x_years |
|
Der heißeste Buyout-Kandidat des Jahres!
2 Kommentare |
sharedeals | translation missing: de.datetime.time_ago_in_words.almost_x_years |
| Titel | Datum |
|---|---|
| MISC Should Ease Into 2026 Smoothly | vor 7 Tagen |
| MISC Group expands dual-fuel fleet through AET's new Suezmax contracts | vor 8 Tagen |
| MISC Orders LNG Dual-Fuel Suezmax Pair in Fleet Renewal Drive | vor 8 Tagen |
| MISC Posted 60% Jump In Q3 Profit To RM541 Million Despite Lower Revenue | vor 8 Tagen |
| MISC 3Q net profit rises 60%, declares dividend of eight sen per share | vor 8 Tagen |
| Diese Aktien könnten Dich auch interessieren | |
|---|---|
| Cannabis Wheaton Income (2 Artikel) | |
| BYD Company (1 Artikel) | |
| CBLT (1 Artikel) | |
| Celgene (1 Artikel) | |
| Alle anzeigen | |